Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Improving cancer outcomes through equity: Interventions tailored for Hispanic families.

Rachael Heitner, Allison Silvers, Rayna Ross et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13556

e13556 Background: People of Hispanic and Latino/a/x ethnicity (collectively referred to here as “Hispanic”) who are livin...

Cervical cancer epidemiology in high-income nations (1990-2023): Three decades of prevention success and emerging disparities.

Ibrahim Balogun, Tapan Ramesh Giri, Kwame Adjei Sefah et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17532

e17532 Background: Cervical cancer rates and deaths have dropped significantly in high-income countries after the start of...

Dynamic, tumor-agnostic ctDNA analysis for MRD detection and longitudinal monitoring in pleural mesothelioma: The Janus-seq academic workflow.

Sergio Marchini, Micaela Piemontese, Luigi Giovanni Cecchi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20065

e20065 Background: Pleural mesothelioma (PM) is an aggressive thoracic malignancy with poor prognosis and limited tools fo...

Association of immune-mediated hepatitis with immune checkpoint inhibitor regimens in advanced hepatocellular carcinoma.

Himanshu Khangwal, Neha Pillai Vinod, Purvy Manhari Ravula et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16200

e16200 Background: Immune checkpoint inhibitors (ICIs) are standard for unresectable/advanced hepatocellular carcinoma (HC...

A phase I trial evaluating an optimized B7-H3xCD3 T cell engager for treatment of solid cancer.

Jonas S. Heitmann, Richard F. Schlenk, Juliane S. Walz et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2667

TPS2667 Background: T cell-based immunotherapy has revolutionized oncological treatment of various malignancies. However,...

Overall survival of first-line amivantamab plus lazertinib in atypical <i>EGFR</i> -mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study.

Joel W. Neal, Byoung Chul Cho, Yongsheng Wang et al. Jun 01, 2026 pp. 8501-8501 10.1200/jco.2026.44.16_suppl.8501

8501 Background: Patients with atypical EGFR -mutated advanced NSCLC have worse lo...

A novel Bayesian approach for assessing associations between ECOG performance status (ECOG-PS) and patient-reported outcomes (PROs) in patients with gastric or gastroesophageal junction (GC/GEJC) adenocarcinoma: Post hoc analysis from the RATIONALE-305 trial.

Marcia Roxana Cruz-Correa, Markus H. Moehler, Crystal S. Denlinger et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16044

e16044 Background: Oncology clinicians rely on ECOG-PS to guide trial eligibility and monitor disease impact, yet it provi...

Cancer screening and site-specific mortality in adults aged ≥ 65 years: A systematic review.

Carla Kimberly Chavarria, Abril Soledad Perez, Beatrice Dal Bianco et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23182

e23182 Background: Cancer screening in older adults is often guided by age-based policies; however, increasing life expect...

Shifting burden of cardiomyopathy deaths among United States cancer patients: A 25-year CDC WONDER analysis.

Pari Kotak, Muhammad Jawad, Vishan Das et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24009

e24009 Background: Cardiomyopathies (CM) are increasingly recognized among patients with cancer. They may develop due to t...

Bronchoscopic pulsed electric field ablation for locally advanced and metastatic NSCLC: A six-patient real-world experience from a rural community hospital.

Joseph Jose Kuruvilla, Sundeep Bekal, Boyd Hehn et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23399

e23399 Background: ALIYA pulsed electric field (PEF) ablation is a bronchoscopic, non-thermal local therapy designed to in...

STING agonist JMKX000197 infusion in patients with malignant pleural effusion: Preliminary results from a prospective phase Ib study.

Ning Li, Shuhang Wang, Ning Jiang et al. Jun 01, 2026 pp. 2598-2598 10.1200/jco.2026.44.16_suppl.2598

2598 Background: Indwelling pleural catheter (IPC) is frequently used for symptomatic malignant pleural effusion (MPE), it...

Reduced-intensity versus intensive induction in high-risk acute promyelocytic leukemia: A systematic review and meta-analysis.

Mohamed M. Khamis, Nehemias Antonio Guevara Rodriguez, Ranju Kunwor Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18521

e18521 Background: High-risk acute promyelocytic leukemia (APL), defined by WBC &gt;10×10⁹/L, accounts for 20-30% of cases...

Osteoporosis and osteoporosis-related fractures among older male cancer patients: A nationwide study.

Tasneem Anagreh, Shila Awal, Laith Sorour et al. Jun 01, 2026 pp. 11196-11196 10.1200/jco.2026.44.16_suppl.11196

11196 Background: Osteoporosis is commonly viewed as a disease of postmenopausal women, leading to significant underdiagno...

Global disparities in current clinical trials in cervical cancer.

Sneha Ahuja, Carl Jay Jainar, Sara Moufarrij et al. Jun 01, 2026 pp. 5530-5530 10.1200/jco.2026.44.16_suppl.5530

5530 Background: Cervical cancer is one of the most disproportionately distributed cancers worldwide, with highest inciden...

Neoadjuvant almonertinib followed by chemo-immunotherapy in II-IIIb EGFR-mutant NSCLC: A single arm, phase II study (NEOVADE).

Jun-Tao Lin, Chao Zhang, Lixu Yan et al. Jun 01, 2026 pp. 8509-8509 10.1200/jco.2026.44.16_suppl.8509

8509 Background: Neoadjuvant target therapy has improved objective response rate (ORR) or major pathological response (MPR...

A phase 2 study of docetaxel (D), ramucirumab (R), and pembrolizumab (P) for patients with metastatic or recurrent non–small cell lung cancer (NSCLC) who progressed on platinum-doublet and PD-1/PD-L1 blockade.

Badi Edmond El Osta, Jennifer W. Carlisle, Conor Ernst Steuer et al. Jun 01, 2026 pp. 8594-8594 10.1200/jco.2026.44.16_suppl.8594

8594 Background: NSCLC treatment (trt) efficacy remains modest after progression on platinum and immune checkpoint inhibit...

Epcoritamab (epcor) + chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) eligible for autologous stem cell transplant (ASCT): Pooled results from arms 4 and 10 of EPCORE NHL-2.

Yasmin Karimi, Pau Abrisqueta, Charalambos Andreadis et al. Jun 01, 2026 pp. 7061-7061 10.1200/jco.2026.44.16_suppl.7061

7061 Background: Pts with R/R LBCL can have inadequate response to salvage treatment (tx), precluding ASCT. While CAR T th...

Comparative safety profiles of frontline BTK inhibitor–containing regimens in mantle cell lymphoma: A cross-trial analysis of phase III studies.

Sameer Bhimani, Taimoor Nasir, Mohamed Daoud et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19049

e19049 Background: Bruton tyrosine kinase inhibitors (BTKis) are increasingly incorporated into frontline mantle cell lymp...

Survival of hematologic malignancy in patients with early-stage chronic kidney disease (SHIP-CKD).

Songphol Tungjitviboonkun, Kevin Shi, Brian Schult et al. Jun 01, 2026 pp. 7089-7089 10.1200/jco.2026.44.16_suppl.7089

7089 Background: Chronic kidney disease (CKD) is a common comorbidity among cancer patients and may influence treatment op...

Redox status of endometrial tumors: A comparative study in endometrioid adenocarcinoma, serous, and clear cell carcinomas.

Irina A. Goroshinskaya, Elena M. Frantsiyants, Irina V. Kaplieva et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17619

e17619 Background: Oxidative stress, reflecting an imbalance between the formation of reactive oxygen species and the body...

Anatomical and clinical heterogeneity of dMMR colorectal cancer by tumor location.

Fei Li, Ping Yang, Tao Jiang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15725

e15725 Background: Deficient mismatch repair (dMMR) colorectal cancer is a biologically heterogeneous disease. Tumors from...

Phase II trial of olaparib and ceralasertib in patients with recurrent osteosarcoma: Lung-only resectable cohort efficacy and correlative biomarker results.

Suzanne J. Forrest, Amanda Marinoff, J. Andrew Livingston et al. Jun 01, 2026 pp. 10015-10015 10.1200/jco.2026.44.16_suppl.10015

10015 Background: Patients with osteosarcoma recurrence have limited treatment options and poor outcomes. The observed res...

Efficacy, survival, and safety of neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: A systematic review and meta-analysis of randomized and real-world comparative studies.

Manas Gunani, Anubhuti Sharma, Arundhati Sharma et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12679

e12679 Background: Neoadjuvant chemotherapy is a standard approach for high-risk early breast cancer, with pathologic comp...

Diagnostic and prognostic performance of urinary metabolomic biomarkers in lung cancer: A systematic review and meta-analysis.

Simran ., Somnath Panda, Kayeong Shin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20551

e20551 Background: Urinary biomarkers offer a non-invasive strategy for the detection and prognostication of lung cancer;...

Clinical and pathological outcomes of patients with germ-cell tumor undergoing surgical resection of residual disease after high-dose chemotherapy.

Ahmed Bilal Khalid, Ritika Bhadouriya, Sandra K. Althouse et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17012

e17012 Background: In patients (pts) with germ-cell tumor (GCT) treated with high-dose chemotherapy (HDCT) and peripheral-...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page